Crossmark

MHY4571, a novel diarylcyclohexanone derivative, exerts anti-cancer activity by regulating the PKA-cAMP-response element-binding protein pathway in squamous cell lung cancer

Crossref DOI link: https://doi.org/10.1186/s40164-022-00324-8

Published Online: 2022-10-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chung, Jae Heun

Choi, Ho Jung

Kang, Yong Jung

Kim, Yun Seong

Lee, Sang-Yull

Kwon, Ryuk Jun

Jeong, Han-Sol

Park, Su-Jung

Jeong, Yeongmu

Kang, Dongwan

Ko, Jeongin

Noh, SangGyun

Chung, Hae Young

Moon, Hyung Ryong

Yoon, Seong Hoon
Funding

Funding for this research was provided by:

National Research Foundation of Korea (NRF) grant, funded by the Korean government (NRF-2020R1F1A1065278, NRF-2021R1F1A1047325)
License Information

Text and Data Mining valid from 2022-10-08

Version of Record valid from 2022-10-08
More Information

Article History

Received: 1 June 2022

Accepted: 26 September 2022

First Online: 8 October 2022

Declarations

:

: This study was approved by the Institutional Animal Care and Use Committee at Pusan National University, Institutional Review Board protocol (04–2017-004) of Pusan National University Yangsan Hospital, and by the Institutional Animal Care and Use Committee of the Laboratory Animal Center at Daegu-Gyeongbuk Medical Innovation Foundation on the grounds of the Animal Protection Act (Enactment May 31, 1991., Act No. 4379, Partial Amendment 20 Jan., 2015, Act No. 12053).

: All authors read and approved the final manuscript.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below